benzinga.comAUG 311 min read$RYTM

Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today - Rhythm Pharmac

Rhythm Pharmaceuticals (RYTM) has outperformed the market over the past 5 years, with an annualized return of 52.06%. A $100 investment 5 years ago would be worth $782.75 today. The company has a market capitalization of $7.42 billion.

Original reporting

benzinga.com

Published Aug 31, 2026, 3:45 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 1, 2026, 1:14 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$RYTM

Neutral

high confidence

Mentioned

$RYTM

Relevance

4/10

AlphAI data visualization · based on benzinga.com

Decision brief

The 30-second read

$RYTMNeutralLow

Why it matters

No new information; the piece serves as a promotional summary of past returns.

Market read

Low relevance for traders; no actionable news.

What to watch

Current valuation, pipeline risk, and upcoming earnings are not addressed.

Relevance 4/10Novelty 2/10Timing: none

Background

Rhythm Pharmaceuticals (NASDAQ:RYTM) is a biotech firm; the article is an automated performance recap.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RYTMNeutralHigh confidence

Context

The article only recaps Rhythm Pharmaceuticals' 5‑year performance with no new corporate event.

Expected impact

None

Evidence & confidence

The content provides no fresh catalyst or data that could move the stock.

Market effects

Sector

None; the article does not affect the broader biotech sector.

Regional

None; no regional market effect is implied.

Global

None

Counterpoint

What could challenge this read

Without a fresh catalyst, the historical return story may overstate current upside.

Key entities

company
Rhythm Pharmaceuticals
Biopharmaceutical company focused on rare disease treatments.

Read at source ← All news

SEP 14

$RYTMMedAI 8/10

Does New Childhood Obesity Data Change The Bull Case For Rhythm Pharmaceuticals (RYTM)?

Rhythm Pharmaceuticals (RYTM) presented new data at the 64th ESPE Meeting, showing positive results for setmelanotide in treating paediatric acquired hypothalamic obesity, including BMI reductions and improved metabolic indices. Analysts note this strengthens the company's clinical story but does not alter its near-term financial losses. The data may support future regulatory and reimbursement progress, with analysts projecting significant revenue growth by 2029.

simplywall.st3 min

SEP 14

$RYTMMed

Rhythm Pharmaceuticals assumed with an Outperform at Leerink

Leerink initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating and $133 price target, citing its leadership in rare obesity treatments and growth prospects.

tipranks.com1 min

SEP 10

$RYTMMedAI 8/10

French children showed lower body-size scores on a rare-obesity drug

Rhythm Pharmaceuticals (RYTM) presented data at ESPE 2026 showing setmelanotide reduced BMI and improved cardiometabolic markers in paediatric hypothalamic obesity patients. Real-world data from France showed mean BMI reductions of 11.5% at 6 months and 9.0% at 18 months. Phase 3 analyses showed significant improvements in metabolic indices compared to placebo.

stocktitan.net3 min

AUG 28

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

finanznachrichten.de3 min

AUG 26

$RYTMMed

Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story

Rhythm Pharmaceuticals (RYTM) received marketing approval in Japan for its drug IMCIVREE. The stock has gained 11% in the past month and 24% in 90 days. Analysts suggest the company may be 15% undervalued, with a fair value estimate of $134, but it trades at a high P/S ratio of 32.5x.

simplywall.st2 min

AUG 24

$RYTMHighAI 8/10

Rhythm Wins Japan Nod For IMCIVREE As First Treatment For Acquired Hypothalamic Obesity; Stock Up

Rhythm Pharmaceuticals (RYTM) received Japanese approval for IMCIVREE to treat acquired hypothalamic obesity, a rare condition. The approval follows a Phase 3 trial showing significant BMI reduction. Rhythm estimates 5,000-8,000 people in Japan have this condition. The UK also expanded IMCIVREE's authorization. RYTM stock is up 0.99% to $110 at close, down 0.72% in pre-market.

rttnews.com2 min